Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
•
Primary Care
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Under what circumstances would you treat prostate cancer without a biopsy?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
